Arbutus Biopharma Statistics
Share Statistics
Arbutus Biopharma has 191.48M
shares outstanding. The number of shares has increased by 1.46%
in one year.
| Shares Outstanding | 191.48M |
| Shares Change (YoY) | 1.46% |
| Shares Change (QoQ) | 1.05% |
| Owned by Institutions (%) | 55.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 336 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 11.05M, so 5.77% of the outstanding
shares have been sold short.
| Short Interest | 11.05M |
| Short % of Shares Out | 5.77% |
| Short % of Float | 7.31% |
| Short Ratio (days to cover) | 7.59 |
Valuation Ratios
The PE ratio is -8.68 and the forward
PE ratio is -35.91.
Arbutus Biopharma's PEG ratio is
0.64.
| PE Ratio | -8.68 |
| Forward PE | -35.91 |
| PS Ratio | 98.35 |
| Forward PS | 3.9 |
| PB Ratio | 6.23 |
| P/FCF Ratio | -9.33 |
| PEG Ratio | 0.64 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Arbutus Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.15,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.15 |
| Quick Ratio | 8.15 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -557.07 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $140,250 |
| Profits Per Employee | $-1,589,090.91 |
| Employee Count | 44 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 26.07% in the
last 52 weeks. The beta is 1.45, so Arbutus Biopharma's
price volatility has been higher than the market average.
| Beta | 1.45 |
| 52-Week Price Change | 26.07% |
| 50-Day Moving Average | 3.31 |
| 200-Day Moving Average | 3.59 |
| Relative Strength Index (RSI) | 58.11 |
| Average Volume (20 Days) | 1,041,456 |
Income Statement
In the last 12 months, Arbutus Biopharma had revenue of 6.17M
and earned -69.92M
in profits. Earnings per share was -0.38.
| Revenue | 6.17M |
| Gross Profit | 4.79M |
| Operating Income | -76.32M |
| Net Income | -69.92M |
| EBITDA | -68.4M |
| EBIT | -69.78M |
| Earnings Per Share (EPS) | -0.38 |
Full Income StatementBalance Sheet
The company has 36.33M in cash and 1.29M in
debt, giving a net cash position of 35.04M.
| Cash & Cash Equivalents | 36.33M |
| Total Debt | 1.29M |
| Net Cash | 35.04M |
| Retained Earnings | -1.35B |
| Total Assets | 131.71M |
| Working Capital | 111.7M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -64.85M
and capital expenditures -182K, giving a free cash flow of -65.03M.
| Operating Cash Flow | -64.85M |
| Capital Expenditures | -182K |
| Free Cash Flow | -65.03M |
| FCF Per Share | -0.35 |
Full Cash Flow StatementMargins
Gross margin is 77.64%, with operating and profit margins of -1236.74% and -1133.04%.
| Gross Margin | 77.64% |
| Operating Margin | -1236.74% |
| Pretax Margin | -1133.04% |
| Profit Margin | -1133.04% |
| EBITDA Margin | -1108.46% |
| EBIT Margin | -1236.74% |
| FCF Margin | -1053.83% |
